Work

Safety and immunogenicity of a DNA-vaccine immunotherapy in men with biochemically (PSA) relapsed prostate cancer

Year: 2017

Type: article

Source: Annals of Oncology

DOI: 10.1093/annonc/mdx370.007

Authors: N.D. Shore, E. Heath, L. Nordquist, H. Cheng, K. Bhatt, M. Morrow, T. McMullan, K. Kraynyak, J. Lee, B. Sacchetta, L. Liu, S. Rosencranz, S.T. Tagawa, R.A. Parikh, R. Tutrone, J. Garcia, Y. Whang, W. Kelly, I. Csiki, M. Bagarazzi

Institutions: The Barbara Ann Karmanos Cancer Institute, Urology Cancer Center and GU Research Network, University of Washington, Inovio Pharmaceuticals (United States), Weill Cornell Medicine, University of Pittsburgh Medical Center, Greater Baltimore Medical Center, Chesapeake Urology Associates, Cleveland Clinic, University of North Carolina at Chapel Hill, UNC Lineberger Comprehensive Cancer Center, Thomas Jefferson University, Sidney Kimmel Cancer Center

Language: English

Topic: Immunotherapy and Immune Responses

Subfield: Immunology

Field: Immunology and Microbiology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W2761727881

FWCI:

Cites:

Cited by: 2

Related to: 10